Pfizer raised the midpoint of its 2026 revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion on August 4, 2026, after the company delivered stronger-than-expected second-quarter results driven by its portfolio of non-COVID products and emerging obesity treatments. The guidance increase reflects confidence in Pfizer’s core business and the growing contribution from recently launched and acquired medicines.
Second-quarter revenue totaled $15.03 billion, up 2.6% year-over-year, with the company’s launched and acquired products surging 18% operationally. Outside of COVID-19 products, revenue grew 5% operationally, signaling the strength of Pfizer’s diversified pipeline beyond pandemic-era treatments.
The revenue guidance revision reflects a split performance across Pfizer’s portfolio. Non-COVID products performed approximately $1.5 billion better than expected, while the company reduced its outlook for COVID-19 products to roughly $4 billion for the year, down from a previous estimate of $5 billion. This adjustment reflects the natural decline in demand for pandemic vaccines and treatments as infection rates normalize globally.
Pfizer’s obesity program emerged as a key driver of momentum. Chief Executive Officer Albert Bourla stated in the earnings release that the company’s “obesity program is advancing with meaningful momentum,” with the company planning to advance more than 20 trials for obesity and related conditions in 2026. Pfizer acquired Metsera in December 2025 for $10 billion, gaining access to ultra-long-acting injectable GLP-1 receptor agonist candidates, and is running Phase 3 studies on these compounds as part of a broader push into the high-growth obesity treatment market.
The company’s oncology portfolio also remained a source of strength, with individual products like Padcev driving significant growth. Padcev, used to treat bladder cancer, posted 23% operational revenue growth in the quarter, driven by increased market share and successful launch uptake in new indications. Lorbrena, a lung cancer treatment, grew 37% operationally.
The guidance raise comes as other major pharmaceutical companies report strong second-quarter results and raise their own outlooks. Merck raised its 2026 sales outlook to $66.3 billion–$67.3 billion after beating second-quarter estimates, while Johnson & Johnson posted $25.3 billion in Q2 2026 sales and raised full-year guidance to approximately $101.1 billion. Eli Lilly’s stock hit a record high on strong earnings momentum in mid-August.
Pfizer reaffirmed its adjusted diluted earnings-per-share guidance of $2.80 to $3.00 for the full year 2026, which absorbs the impact of a $650 million in-process R&D charge related to a licensing agreement with Innovent Biologics. The company also announced an additional $2.5 billion in anticipated productivity enhancement savings expected to be realized from 2027 through 2029.
Pfizer stock received a Buy rating from BMO Capital following the earnings beat, reflecting analyst confidence in the company’s strategic positioning and execution. The stock initially rose 1.5% to close at $25.41 on the day of the earnings announcement.
Sources
- Pfizer press release — official Q2 2026 earnings report and 2026 guidance raise
- Morningstar — Pfizer’s revenue guidance lift and quarterly results
- Quartz — confirmation of new 2026 revenue guidance range
- Seeking Alpha — Pfizer’s $500 million guidance raise at midpoint
- Investors.com — Pfizer stock reaction on August 4, 2026
- BiopharmDive — Pfizer obesity program and clinical trial pipeline
